EPISODE · Jun 1, 2026 · 26 MIN
RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer
from Oncology Brothers: Practice-Changing Cancer Discussions · host Oncology Brothers
Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting.We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively.Topics Covered:Overview of the RASolute-302 studyImpact of Daraxonrasib on overall survivalRAS mutations in pancreatic cancerMechanism of action of RAS inhibitorsSide effects and management strategiesTune in now for an enlightening discussion on the future of pancreatic cancer treatment!Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/#ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival
What this episode covers
Join us as we bring you the latest insights from ASCO 2026! In this episode, we dived deep into the groundbreaking RASolute-302 study, which has made waves in the treatment of metastatic pancreatic cancer. Discover how the novel RAS inhibitor, Daraxonrasib, has doubled overall survival rates from 6.7 months to an impressive 13.2 months for patients in the second-line setting.We were joined by esteemed experts Dr. Rachna Shroff, Dr. Shubham Pant, Dr. Eileen O'Reilly, and Dr. Andrew Ko, who shared their insights on the study's design, findings, and the implications for our clinical practice. We touched on the prevalence of RAS mutations in pancreatic cancer, the mechanism of action of Daraxonrasib, and the side effect profile that clinicians need to manage effectively.Topics Covered:Overview of the RASolute-302 studyImpact of Daraxonrasib on overall survivalRAS mutations in pancreatic cancerMechanism of action of RAS inhibitorsSide effects and management strategiesTune in now for an enlightening discussion on the future of pancreatic cancer treatment!Listen us on:Apple Podcast: https://podcasts.apple.com/us/podcast/oncology-brothers-practice-changing-cancer-discussions/id1653340966Follow us on social media:X/Twitter: https://twitter.com/oncbrothersInstagram: https://www.instagram.com/oncbrothersWebsite: https://oncbrothers.com/#ASCO2026, #PancreaticCancer, #Daraxonrasib, #RASmutation, #OverallSurvival
NOW PLAYING
RASolute-302 with Daraxonrasib - Game Changer at ASCO 2026 in Pancreatic Cancer
No transcript for this episode yet
Similar Episodes
Mar 31, 2026 ·54m
Mar 27, 2026 ·14m
Mar 24, 2026 ·42m
Mar 20, 2026 ·42m
Mar 17, 2026 ·41m
Mar 13, 2026 ·44m